Matthew Barcus
Stock Analyst at Chardan Capital
(2.47)
# 2,282
Out of 5,182 analysts
21
Total ratings
25%
Success rate
34.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Barcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Buy | $12 → $10 | $5.81 | +72.12% | 3 | Mar 26, 2025 | |
| QURE uniQure | Maintains: Buy | $45 → $27 | $17.58 | +53.58% | 4 | Jun 22, 2023 | |
| XLO Xilio Therapeutics | Reiterates: Buy | $98 | $8.57 | +1,043.52% | 3 | May 30, 2023 | |
| IMVT Immunovant | Maintains: Buy | $21 → $32 | $29.30 | +9.22% | 4 | May 23, 2023 | |
| PPBT Purple Biotech | Reiterates: Buy | $2,200 | $4.87 | +45,074.54% | 3 | May 17, 2023 | |
| ANIX Anixa Biosciences | Reiterates: Buy | $9 | $2.91 | +209.28% | 3 | Apr 18, 2023 | |
| IMNM Immunome | Maintains: Buy | $9 → $8 | $24.63 | -67.52% | 1 | Mar 17, 2023 |
Zura Bio
Mar 26, 2025
Maintains: Buy
Price Target: $12 → $10
Current: $5.81
Upside: +72.12%
uniQure
Jun 22, 2023
Maintains: Buy
Price Target: $45 → $27
Current: $17.58
Upside: +53.58%
Xilio Therapeutics
May 30, 2023
Reiterates: Buy
Price Target: $98
Current: $8.57
Upside: +1,043.52%
Immunovant
May 23, 2023
Maintains: Buy
Price Target: $21 → $32
Current: $29.30
Upside: +9.22%
Purple Biotech
May 17, 2023
Reiterates: Buy
Price Target: $2,200
Current: $4.87
Upside: +45,074.54%
Anixa Biosciences
Apr 18, 2023
Reiterates: Buy
Price Target: $9
Current: $2.91
Upside: +209.28%
Immunome
Mar 17, 2023
Maintains: Buy
Price Target: $9 → $8
Current: $24.63
Upside: -67.52%